[A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed].
Identifieur interne : 000023 ( Main/Exploration ); précédent : 000022; suivant : 000024[A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed].
Auteurs : Miquel B. Ekkelenkamp ; C H Van Werkhoven ; Patricia C J. Bruijning-Verhagen ; Marc J M. BontenSource :
- Nederlands tijdschrift voor geneeskunde [ 1876-8784 ] ; 2018.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Analyse coût-bénéfice (MeSH), Essais contrôlés randomisés comme sujet (normes), Essais contrôlés randomisés comme sujet (éthique), Grippe humaine (prévention et contrôle), Hospitalisation (statistiques et données numériques), Humains (MeSH), Méthode en double aveugle (MeSH), Pays-Bas (MeSH), Sujet âgé (MeSH), Vaccination (économie), Vaccins antigrippaux (économie).
- MESH :
- normes : Essais contrôlés randomisés comme sujet.
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Hospitalisation.
- économie : Vaccination, Vaccins antigrippaux.
- éthique : Essais contrôlés randomisés comme sujet.
- Adulte d'âge moyen, Analyse coût-bénéfice, Humains, Méthode en double aveugle, Pays-Bas, Sujet âgé.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Aged (MeSH), Cost-Benefit Analysis (MeSH), Double-Blind Method (MeSH), Hospitalization (statistics & numerical data), Humans (MeSH), Influenza Vaccines (economics), Influenza, Human (prevention & control), Middle Aged (MeSH), Netherlands (MeSH), Outcome Assessment, Health Care (MeSH), Randomized Controlled Trials as Topic (ethics), Randomized Controlled Trials as Topic (standards), Vaccination (economics).
- MESH :
- chemical , economics : Influenza Vaccines.
- geographic : Netherlands.
- economics : Vaccination.
- ethics : Randomized Controlled Trials as Topic.
- prevention & control : Influenza, Human.
- standards : Randomized Controlled Trials as Topic.
- statistics & numerical data : Hospitalization.
- Aged, Cost-Benefit Analysis, Double-Blind Method, Humans, Middle Aged, Outcome Assessment, Health Care.
Abstract
Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.
PubMed: 30306759
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed].</title><author><name sortKey="Ekkelenkamp, Miquel B" sort="Ekkelenkamp, Miquel B" uniqKey="Ekkelenkamp M" first="Miquel B" last="Ekkelenkamp">Miquel B. Ekkelenkamp</name><affiliation><nlm:affiliation>UMC Utrecht, afd. Medische Microbiologie.</nlm:affiliation><wicri:noCountry code="subField">afd</wicri:noCountry></affiliation></author><author><name sortKey="Van Werkhoven, C H" sort="Van Werkhoven, C H" uniqKey="Van Werkhoven C" first="C H" last="Van Werkhoven">C H Van Werkhoven</name><affiliation><nlm:affiliation>Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</nlm:affiliation><wicri:noCountry code="no comma">Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Contact: C.H. van Werkhoven (c.h.vanwerkhoven@umcutrecht.nl).</nlm:affiliation><wicri:noCountry code="no comma">Contact: C.H. van Werkhoven (c.h.vanwerkhoven@umcutrecht.nl).</wicri:noCountry></affiliation></author><author><name sortKey="Bruijning Verhagen, Patricia C J" sort="Bruijning Verhagen, Patricia C J" uniqKey="Bruijning Verhagen P" first="Patricia C J" last="Bruijning-Verhagen">Patricia C J. Bruijning-Verhagen</name><affiliation><nlm:affiliation>Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</nlm:affiliation><wicri:noCountry code="no comma">Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</wicri:noCountry></affiliation></author><author><name sortKey="Bonten, Marc J M" sort="Bonten, Marc J M" uniqKey="Bonten M" first="Marc J M" last="Bonten">Marc J M. Bonten</name><affiliation><nlm:affiliation>UMC Utrecht, afd. Medische Microbiologie.</nlm:affiliation><wicri:noCountry code="subField">afd</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30306759</idno><idno type="pmid">30306759</idno><idno type="wicri:Area/Main/Corpus">000026</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000026</idno><idno type="wicri:Area/Main/Curation">000026</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000026</idno><idno type="wicri:Area/Main/Exploration">000026</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed].</title><author><name sortKey="Ekkelenkamp, Miquel B" sort="Ekkelenkamp, Miquel B" uniqKey="Ekkelenkamp M" first="Miquel B" last="Ekkelenkamp">Miquel B. Ekkelenkamp</name><affiliation><nlm:affiliation>UMC Utrecht, afd. Medische Microbiologie.</nlm:affiliation><wicri:noCountry code="subField">afd</wicri:noCountry></affiliation></author><author><name sortKey="Van Werkhoven, C H" sort="Van Werkhoven, C H" uniqKey="Van Werkhoven C" first="C H" last="Van Werkhoven">C H Van Werkhoven</name><affiliation><nlm:affiliation>Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</nlm:affiliation><wicri:noCountry code="no comma">Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</wicri:noCountry></affiliation><affiliation><nlm:affiliation>Contact: C.H. van Werkhoven (c.h.vanwerkhoven@umcutrecht.nl).</nlm:affiliation><wicri:noCountry code="no comma">Contact: C.H. van Werkhoven (c.h.vanwerkhoven@umcutrecht.nl).</wicri:noCountry></affiliation></author><author><name sortKey="Bruijning Verhagen, Patricia C J" sort="Bruijning Verhagen, Patricia C J" uniqKey="Bruijning Verhagen P" first="Patricia C J" last="Bruijning-Verhagen">Patricia C J. Bruijning-Verhagen</name><affiliation><nlm:affiliation>Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</nlm:affiliation><wicri:noCountry code="no comma">Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</wicri:noCountry></affiliation></author><author><name sortKey="Bonten, Marc J M" sort="Bonten, Marc J M" uniqKey="Bonten M" first="Marc J M" last="Bonten">Marc J M. Bonten</name><affiliation><nlm:affiliation>UMC Utrecht, afd. Medische Microbiologie.</nlm:affiliation><wicri:noCountry code="subField">afd</wicri:noCountry></affiliation></author></analytic><series><title level="j">Nederlands tijdschrift voor geneeskunde</title><idno type="eISSN">1876-8784</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Double-Blind Method (MeSH)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (prevention & control)</term><term>Middle Aged (MeSH)</term><term>Netherlands (MeSH)</term><term>Outcome Assessment, Health Care (MeSH)</term><term>Randomized Controlled Trials as Topic (ethics)</term><term>Randomized Controlled Trials as Topic (standards)</term><term>Vaccination (economics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Essais contrôlés randomisés comme sujet (normes)</term><term>Essais contrôlés randomisés comme sujet (éthique)</term><term>Grippe humaine (prévention et contrôle)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Humains (MeSH)</term><term>Méthode en double aveugle (MeSH)</term><term>Pays-Bas (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="ethics" xml:lang="en"><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="éthique" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cost-Benefit Analysis</term><term>Double-Blind Method</term><term>Humans</term><term>Middle Aged</term><term>Outcome Assessment, Health Care</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Humains</term><term>Méthode en double aveugle</term><term>Pays-Bas</term><term>Sujet âgé</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30306759</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1876-8784</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><PubDate><Year>2018</Year><Month>09</Month><Day>06</Day></PubDate></JournalIssue><Title>Nederlands tijdschrift voor geneeskunde</Title><ISOAbbreviation>Ned Tijdschr Geneeskd</ISOAbbreviation></Journal><ArticleTitle>[A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed].</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">D3285</ELocationID><Abstract><AbstractText>Based on current research, there are no valid reasons to assume that influenza vaccination of people aged 60 and over without any other medical indications, in the context of the national programme of influenza prevention, leads to significant, relevant and cost-effective health benefits. In view of the pressure on health care budgets and the decreasing social willingness to vaccinate, it is of great and urgent importance that the actual effect of influenza vaccination is quantified in a double-blind placebo-controlled randomized trial (RCT) with relevant outcome measures, which does not suffer from the methodological shortcomings of the few previous studies. In order to demonstrate a 10% reduction in hospitalisation for respiratory infections, this RCT should include approximately 100,000 subjects and follow these participants for three years. We consider such a trial feasible in the Dutch situation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ekkelenkamp</LastName><ForeName>Miquel B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>UMC Utrecht, afd. Medische Microbiologie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Werkhoven</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Contact: C.H. van Werkhoven (c.h.vanwerkhoven@umcutrecht.nl).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruijning-Verhagen</LastName><ForeName>Patricia C J</ForeName><Initials>PCJ</Initials><AffiliationInfo><Affiliation>Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonten</LastName><ForeName>Marc J M</ForeName><Initials>MJM</Initials><AffiliationInfo><Affiliation>UMC Utrecht, afd. Medische Microbiologie.</Affiliation></AffiliationInfo></Author></AuthorList><Language>dut</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Een trial naar het effect van influenzavaccinatie bij ouderen.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ned Tijdschr Geneeskd</MedlineTA><NlmUniqueID>0400770</NlmUniqueID><ISSNLinking>0028-2162</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000941" MajorTopicYN="Y">ethics</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30306759</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Bonten, Marc J M" sort="Bonten, Marc J M" uniqKey="Bonten M" first="Marc J M" last="Bonten">Marc J M. Bonten</name><name sortKey="Bruijning Verhagen, Patricia C J" sort="Bruijning Verhagen, Patricia C J" uniqKey="Bruijning Verhagen P" first="Patricia C J" last="Bruijning-Verhagen">Patricia C J. Bruijning-Verhagen</name><name sortKey="Ekkelenkamp, Miquel B" sort="Ekkelenkamp, Miquel B" uniqKey="Ekkelenkamp M" first="Miquel B" last="Ekkelenkamp">Miquel B. Ekkelenkamp</name><name sortKey="Van Werkhoven, C H" sort="Van Werkhoven, C H" uniqKey="Van Werkhoven C" first="C H" last="Van Werkhoven">C H Van Werkhoven</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000023 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000023 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30306759
|texte= [A trial to study the effect of influenza vaccination in the elderly: ethical, feasible and badly needed].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30306759" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |